000274376 001__ 274376
000274376 005__ 20240229154932.0
000274376 0247_ $$2doi$$a10.1007/s00120-023-02062-z
000274376 0247_ $$2pmid$$apmid:36941382
000274376 0247_ $$2ISSN$$a2731-7064
000274376 0247_ $$2ISSN$$a0042-1103
000274376 0247_ $$2ISSN$$a0340-2592
000274376 0247_ $$2ISSN$$a1433-0563
000274376 0247_ $$2ISSN$$a2731-7072
000274376 037__ $$aDKFZ-2023-00576
000274376 041__ $$aGerman
000274376 082__ $$a610
000274376 1001_ $$0P:(DE-HGF)0$$aHandke, Analena Elisa$$b0
000274376 245__ $$aSystematic or targeted fusion-guided biopsy.[Systematische oder gezielte Fusionsbiopsie der Prostata.]
000274376 260__ $$aNew York]$$bSpringer Medizin$$c2023
000274376 3367_ $$2DRIVER$$aarticle
000274376 3367_ $$2DataCite$$aOutput Types/Journal article
000274376 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1683788744_11662$$xReview Article
000274376 3367_ $$2BibTeX$$aARTICLE
000274376 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000274376 3367_ $$00$$2EndNote$$aJournal Article
000274376 500__ $$a#LA:E010# / 2023 May;62(5):464-472
000274376 520__ $$aEarly detection of prostate cancer (PCa) is associated with a high risk for detecting low-risk disease. In the primary biopsy indication, systematic biopsy leads to an increased detection of clinically insignificant PCa, and significant prostate cancers are not detected with sufficient sensitivity, especially without prior magnetic resonance imaging (MRI). Similar data have recently become available for PCa screening.In light of the current literature, this article aims to discuss the data on systematic and combined targeted and systematic multiparametric MRI (mpMRI)-guided fusion biopsy to improve PCa diagnosis in clinically suspected cancer even in screening using multivariable risk stratification.Literature review on mpMRI and MRI/TRUS fusion biopsy (TRUS: transrectal ultrasonography) for tumor detection in suspected prostate cancer and PCa screening was performed.Multiparametric MRI as a reflex test after prostate-specific antigen (PSA) determination (PSA cut-off 4 ng/ml) in combination with targeted biopsy alone reduces the detection of clinically nonsignificant tumors in early detection by half. On the other hand, in the form of a target saturation or in combination with a systematic biopsy, the sensitivity for the detection of cancers of International Society of Urogenital Pathology (ISUP) grade groups 2 or higher can be improved. Similar results are also shown in PCa screening with a PSA cut-off of 3 ng/ml.The evidence for performing a targeted fusion biopsy alone is currently insufficient. Therefore, the combination of mpMRI-guided targeted and systematic biopsy continues to be the recommended standard for prostate cancer diagnosis.
000274376 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000274376 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000274376 650_7 $$2Other$$aMultiparametric MRI
000274376 650_7 $$2Other$$aOverdiagnosis
000274376 650_7 $$2Other$$aProstate cancer
000274376 650_7 $$2Other$$aProstate-specific antigen
000274376 650_7 $$2Other$$aRisk stratification
000274376 7001_ $$0P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aAlbers, Peter$$b1$$udkfz
000274376 7001_ $$aSchimmöller, Lars$$b2
000274376 7001_ $$0P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aBonekamp, David$$b3$$udkfz
000274376 7001_ $$aAsbach, Patrick$$b4
000274376 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b5$$udkfz
000274376 7001_ $$0P:(DE-HGF)0$$aHadaschik, Boris A$$b6
000274376 7001_ $$0P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aRadtke, Jan Philipp$$b7$$eLast author$$udkfz
000274376 773__ $$0PERI:(DE-600)3123197-4$$a10.1007/s00120-023-02062-z$$n5$$p464-472$$tDie Urologie$$v62$$x2731-7064$$y2023
000274376 909CO $$ooai:inrepo02.dkfz.de:274376$$pVDB
000274376 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000274376 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000274376 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea098e4d78abeb63afaf8c25ec6d6d93$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000274376 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000274376 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000274376 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79897f8897ff77676549d9895258a0f2$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000274376 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000274376 9141_ $$y2023
000274376 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-08$$wger
000274376 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-08$$wger
000274376 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-08
000274376 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-08
000274376 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-08
000274376 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-22
000274376 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-22
000274376 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-22
000274376 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-22
000274376 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-22
000274376 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-22
000274376 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bUROLOGIE : 2022$$d2023-08-22
000274376 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-22
000274376 9202_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x0
000274376 9201_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000274376 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x1
000274376 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK ED ES zentral$$x2
000274376 980__ $$ajournal
000274376 980__ $$aVDB
000274376 980__ $$aI:(DE-He78)C130-20160331
000274376 980__ $$aI:(DE-He78)E010-20160331
000274376 980__ $$aI:(DE-He78)ED01-20160331
000274376 980__ $$aUNRESTRICTED